Author

Futang Yang

ORCID: 0009-0003-4559-8608

Observed ORCID: 0009-0003-4559-8608

OpenAlex ID: A5047118710

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study

2026 · Lin Shen, Xiaotian Zhang, et al. · The Lancet · 17

A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer

2024 · Ning Li, Meng Qiu, et al. · Med · 10

Neoadjuvant/adjuvant serplulimab vs. placebo combined with chemotherapy for PD-L1–positive gastric cancer: A randomized, double-blind, multicenter phase 3 study.

2026 · Lin Shen, Xiaotian Zhang, et al. · Journal of Clinical Oncology · 1

Updated results of HLX22 plus trastuzumab and XELOX for first-line treatment of human epidermal growth factor receptor 2 (HER2)–positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC).

2025 · Jin Li, Ning Li, et al. · Journal of Clinical Oncology · 1

Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial

2025 · Binghe Xu, Qingyuan Zhang, et al. · The Breast · 1

HLX22 plus trastuzumab and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): Updated results with additional patients.

2025 · Jin Li, Ning Li, et al. · Journal of Clinical Oncology · 1

HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind, multicenter phase 2 study.

2024 · Jin Li, Yong Gao, et al. · Journal of Clinical Oncology · 1

Neoadjuvant Pertuzumab Biosimilar HLX11 versus Reference Pertuzumab for Early-Stage or Locally Advanced Breast Cancer: A Phase III Equivalence Trial

2026 · Jin Zhang, Jinhai Zhu, et al. · Clinical Cancer Research

HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial

2026 · Changxing Li, Kang Zeng, et al. · Therapeutic Advances in Medical Oncology

Abstract 4395: A best-in-class HER2xHER2 novel biparatopic antibody-drug conjugate with an efficacious, low-toxicity design that maximizes antibody functionality

2026 · Ge Song, Yushi Chi, et al. · Cancer Research

A randomized, double-blinded, international phase III trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJ cancer.

2026 · Jaffer A. Ajani, Ken Kato, et al. · Journal of Clinical Oncology

A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors.

2025 · Ching-Liang Ho, Tsu-Yi Chao, et al. · Journal of Clinical Oncology

O22 Efficacy and safety of serplulimab, a novel anti-programmed death-1 antibody, in chronic hepatitis B patients

2022 · Cheng-Yuan Peng, Chia-Yen Dai, et al. · Gut

A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.

2022 · Ching-Liang Ho, Tsu-Yi Chao, et al. · Journal of Clinical Oncology

Works count: 14

Citation count: 32

H-index: 2

I10-index: 2